DGAP-Adhoc: ADO Properties S.A.: ADO Properties

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 13, 2016 at 3:30 PM

DGAP-Adhoc: ADO Properties S.A.: ADO Properties successfully places 5,600,001 new shares, generating gross proceeds of EUR 198.8 million

ADO Properties S.A. / Key word(s): Capital Increase 13.09.2016 21:22 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada or Japan or any other jurisdiction in which the distribution or release would be unlawful. ADO Properties S.A.: ADO Properties successfully places 5,600,001 new shares, generating gross proceeds of EUR 198.8 million 5,600,001 new shares have been placed at a placement price of EUR 35.50 per share, resulting in gross proceeds of EUR 198.8 million Proceeds to be used to fund add-on acquisitions of residential properties or portfolios in Berlin, CAPEX investments into existing residential properties and portfolios, future growth of the Company and general corporate purposes Current acquisition pipeline of c. EUR 300 million under review by ADO Berlin, 13 September 2016: ADO Properties S.A. ("ADO Properties" or the "Company") has placed 5,600,001 new shares with institutional investors and qualified investors at EUR 35.50 per share by means of an accelerated bookbuild offering. The gross proceeds resulting from the transaction amount to EUR 198.8 million. The Company intends to use the net proceeds to fund add-on acquisitions of residential properties or portfolios in Berlin, CAPEX investments into existing residential properties and portfolios, future growth of the Company and general corporate purposes. ADO Properties is currently in various phases of analysis for potential acquisitions with a total acquisition volume of c. EUR 300 million which, if successful, could be completed within the next six months. The Placement Shares will entitle their holders to full dividend rights as from 1 January 2016 (not including the annual dividend for the Company's financial year ended 31 December 2015 as paid on 6 May 2016). The new shares are expected to be admitted to listing and trading on 15 September 2016 and shall be included in the existing quotation on the sub- segment of the regulated market with additional post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange as from 16 September 2016. Settlement of the transaction is expected to take place on 16 September 2016. The Company has committed to a lock up period of 90 days and ADO Group Ltd has committed to a lock-up period of 90 days, except in case of enforcement of an already existing share pledge on part of its shares for its bond issuance or a future share pledge in relation to future financing of ADO Group Ltd following closing of the Placement. Disclaimer This announcement does not contain or constitutes an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. This release is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Any public offering of securities to be made in the United States of America would be made by means of a prospectus that could be obtained from the Company and would contain detailed information about the Company and management, as well as financial statements. There will be no public offer of securities in the United States of America. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. 13.09.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: ADO Properties S.A. 20 rue Eugène Ruppert L-2453 Luxembourg Grand Duchy of Luxembourg Phone: +352 26 493 412 Fax: +352 27 860 722 E-mail: ir@ado.properties Internet: www.ado.immo ISIN: LU1250154413 WKN: A14U78 Indices: SDAX, FTSE EPRA/NAREIT Global Index, FTSE EPRA/NAREIT Developed Europe Index, FTSE EPRA/NAREIT Germany Index Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Photocure Navigates AssureMDx's Medicare Journey

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Segway Powersports Ventures into Baja 1000: Ambitions Run High

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

UAE Pioneers eATA Carnet System Beyond Europe

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Valmet Expands Board Maker Deal in Asia With New Line

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

AI Agents Redefine Finance: Deutsche & Ant Tech

AI Agents: Shaping the Future of Finance The finance world has always been about numbers and precision, but now, with the advent of AI, it’s entering a domain where machines could call the shots. Hold your horses before you imagine free-wheeling robots in suits; this is still the finance sector, where control and audits are holy grails. Deutsche Bank and Ant's Ambitious...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...